Overall survival benefit of androgen suppression in addition to dose-escalated external beam radiotherapy for high-risk prostate cancer: Nationwide real-world data indicates a shift in men that benefit.

MLA

Heesterman, Berdine L., et al. “Overall Survival Benefit of Androgen Suppression in Addition to Dose-Escalated External Beam Radiotherapy for High-Risk Prostate Cancer: Nationwide Real-World Data Indicates a Shift in Men That Benefit.” Urologic Oncology, vol. 42, no. 8, Aug. 2024, p. 245.e9-245.e18. EBSCOhost, https://doi.org/10.1016/j.urolonc.2024.04.013.

APA

Heesterman, B. L., Aben, K. K. H., van den Bergh, A. C. M., van der Voort van Zyp, J. R. N., & Bokhorst, L. P. (2024). Overall survival benefit of androgen suppression in addition to dose-escalated external beam radiotherapy for high-risk prostate cancer: Nationwide real-world data indicates a shift in men that benefit. Urologic Oncology, 42(8), 245.e9-245.e18. https://doi.org/10.1016/j.urolonc.2024.04.013

Chicago

Heesterman, Berdine L, Katja K H Aben, Alfons C M van den Bergh, Jochem R N van der Voort van Zyp, and Leonard P Bokhorst. 2024. “Overall Survival Benefit of Androgen Suppression in Addition to Dose-Escalated External Beam Radiotherapy for High-Risk Prostate Cancer: Nationwide Real-World Data Indicates a Shift in Men That Benefit.” Urologic Oncology 42 (8): 245.e9-245.e18. doi:10.1016/j.urolonc.2024.04.013.